Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.
Pinter J. et al, (2024), Syst Rev, 13
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A. et al, (2024), J Hematol Oncol, 17
Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
Braybrooke J. et al, (2024), Lancet, 403
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi J-A. et al, (2024), Leukemia, 38, 281 - 290
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2023), Lancet, 402, 1991 - 2003
Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
Taylor P. et al, (2023), J Clin Endocrinol Metab, 108, 2615 - 2625
Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.
Hills RK., (2023), Br J Haematol
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Freeman SD. et al, (2023), Blood
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills RK. et al, (2023), Journal of Clinical Oncology, 41, 508 - 508
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk None. and Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) None., (2023), Lancet, 401, 1277 - 1292
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills RK. et al, (2023), JOURNAL OF CLINICAL ONCOLOGY, 41
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
Gray RG. et al, (2023), JOURNAL OF CLINICAL ONCOLOGY, 41
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Othus M. et al, (2022), Leuk Lymphoma, 1 - 3
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.
Bewicke-Copley F. et al, (2022), Blood Adv
Unified classification and risk-stratification in Acute Myeloid Leukemia.
Tazi Y. et al, (2022), Nat Commun, 13